HANCOCK JAFFE LABORATORIES, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • May 14th, 2018 • Hancock Jaffe Laboratories, Inc. • Surgical & medical instruments & apparatus • New York
The Representative agrees that, if the undersigned is an executive officer or director of the Company, at least three (3) business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of Lock-Up Securities, the Representative will notify the Company of the impending release or waiver; and the Company has agreed in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service at least two (2) business days before the effective date of the release or waiver. Any release or waiver granted by the Representative hereunder to any such officer or director shall only be effective two (2) business days after the publication date of such press release. The provisions of this paragraph will not apply if (a) the release or waiver is effected solely to permit a transfer of Lock-Up Securities not for consideration and (b) the transferee has agreed in writing to be bound by the same t
WARRANT AGREEMENTWarrant Agreement • May 14th, 2018 • Hancock Jaffe Laboratories, Inc. • Surgical & medical instruments & apparatus • Delaware
This Warrant Agreement (“Warrant Agreement”) is made as of ________, 2018, by and between Hancock Jaffe Laboratories, Inc., a Delaware corporation, with offices at 70 Doppler, Irvine, California 92618 (the “Company”), and VStock Transfer, LLC, with offices at 18 Lafayette Place, Woodmere, New York (the “Warrant Agent”).
SECOND AMENDMENT TO PROMISSORY NOTEPromissory Note • May 14th, 2018 • Hancock Jaffe Laboratories, Inc. • Surgical & medical instruments & apparatus • California
This Second Amendment to Promissory Note (this “Second Amendment”), dated as of April 26, 2018 is by and among Hancock Jaffe Laboratories, Inc., a Delaware corporation (the “Company”), and Leman Cardiovascular S.A. (the “Lender”) and further amends that certain Promissory Note, issued by the Company to the Lender on May 10, 2013 (the “Note”).
HANCOCK JAFFE LABORATORIES, INC.Hancock Jaffe Laboratories, Inc. • May 14th, 2018 • Surgical & medical instruments & apparatus
This letter is intended to memorialize our discussions with respect to certain requests that you have made to assign amounts owed to you pursuant to your employment agreement with Hancock Jaffe Laboratories, Inc. (“Hancock Jaffe”) dated August 30, 2016 and as amended on April 2, 2018 (collectively the “Employment Agreement”), and with respect to your willingness to accept a portion of the deferred compensation owed to you pursuant to the Employment Agreement in shares of Hancock Jaffe common stock.
